Status and phase
Conditions
Treatments
About
The primary objective of this study is to evaluate the ability to recruit and retain participants, and to successfully conduct a psilocybin-based protocol, for a study of the treatment of distress related to stage IV or inoperable gastrointestinal cancers. Secondary objectives include pre/post, and longitudinal measurement of distress in intervention participants and a paired family member who is in an observational arm.
Full description
Participants with stage IV or inoperable gastrointestinal cancers are eligible for intervention, paired family member recruited for observational arm. Following preparatory sessions in outpatient palliative care clinic or by telehealth (2-4 sessions lasting 60-90 minutes each), psilocybin will be administered as a 25mg capsule during an 8-hour monitored session. Integration sessions (2-3 sessions lasting up to 90 minutes each) will take place in the outpatient palliative care clinic or by phone or tele-heath. Primary and secondary objectives are complete at one-week post treatment, longitudinal exploratory measures collected up to 12 months post baseline.
Parallel assessment of health care utilization, including choices regarding anti-cancer treatment and resource utilization, and family member distress, family communication, well-being and bereavement will be conducted at concurrent time points.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Long-term or unstable psychiatric illness that would prevent safe cessation of psychotropic drugs including MAOIs, lithium, or anti-psychotics
Severe symptoms of depression or anxiety warranting immediate impatient evaluation or treatment
High-risk of suicide, as measured by Columbia Suicide Severity rating Scale
Current or prior history of schizophrenia, psychotic disorder (unless substance induced or due to medical condition) or bipolar I or II disorder
First-degree family member with schizophrenia, psychotic disorder (unless substance induced or due to medical condition) or bipolar I or II disorder
Conditions known to be incompatible with establishment of rapport or safe exposure to psilocybin including dissociative disorder, borderline personality, traumatic brain injury, obsessive compulsive disorder, anorexia nervosa, or bulimia nervosa
Alcohol or recreational drug abuse disorder, excluding caffeine and nicotine
Known CNS metastases or other major CNS disease such as seizure disorder, dementia, Parkinson's disease, multiple sclerosis
Receive treatment in another clinical trial involving an investigational product for the treatment of cancer during the interventional stage of the protocol
Advanced hepatic dysfunction as indicated by a Child-Pugh Score of C
Renal dysfunction as indicated by creatinine clearance <40 ml/min using the Cockroft-Gault equation
Cardiac or circulatory dysfunction defined as uncontrolled hypertension (systolic blood pressure > 140 or diastolic blood pressure >90 mmHg on three separate readings), angina, stroke or myocardial infarction in the prior 6 months, or claudication
History of seizures
Unable to skip a meal (lunch), or have diabetes which requires administration of medication more than twice daily, or with symptomatic hypoglycemia within the prior 30 days
Pregnant or breastfeeding
Currently using any of the following potent metabolic inducers or inhibitors
Metal in body (i.e. hearing aid, cardiac pacemaker, bone plates, braces, non-removeable piercings/implants, etc.) claustrophobia, inability to lay still for one-hour, or any other condition that would preclude MRI scanning
Primary purpose
Allocation
Interventional model
Masking
24 participants in 2 patient groups
Loading...
Central trial contact
Evelyn Cantril; Taylor A Johnson, BS, MA
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal